Key Takeaways
- Q3 hit by developed-market slowdown: Revenue dipped QoQ as discretionary spending on nutraceuticals weakened in the EU and US, compounded by a pass-through drop in ocean freight that mechanically reduced CIF revenue.
- Realization, not volume, drove 9M growth: 9M revenue rose on a 17% realization gain against just ~2% volume growth, reflecting a high-margin mix shift while utilization ran near peak.
- New capacity is the FY24 story: Dahej and Jhagadia expansions totaling ₹58–60 cr are set to commission in Q2 FY24, with sales expected on the balance sheet by Q3 FY24, though Dahej faces a 2–3 month delay.
- Diversification bets are tiny and delayed: Premix and OTC will contribute only a couple of crores each this year, well below earlier estimates, while API and acquisition plans remain exploratory.
- What to watch next quarter: Whether Q4 volumes recover as management hopes, the firming of the ONGC Dahej O&M contract scope, and any progress on the environmental clearance for the CCS plant.
Demand & Volume
- Developed-market softness: A slight slowdown in demand from the EU and US hit Q3 volumes, as customers restricted discretionary spending on nutraceutical and nutritional products. Management called it temporary and expects Q4 to improve.
- Volume growth was already muted: Even before the Q3 dip, 9M volume growth was only ~2% because the company was already operating at peak capacity utilization.
- Full-year volume: Management expects FY23 volume to land somewhere around 13,000 odd nearly 14,000 metric tons.
- Q4 run-rate estimate: Management endorsed ₹80 cr/quarter as a very fair estimate for the next 3 quarters (Q4 FY23, Q1 FY24, Q2 FY24).
Amit Raj Sinha: "What we have seen in the last couple of months is that there has been a slight slowdown in our demand understanding from the developed markets. That's primarily the EU and the US region. We believe that it is kind of temporary and hopefully we will have the 4th quarter being better than the 3rd quarter."
Revenue Mechanics: Realization, Freight & Mix
- Realization drove 9M growth: A 17% increase in realization, driven by a focus on high-margin product mix, was the primary 9M revenue driver, while volume contributed only ~2%.
- Q3 YoY growth was far more modest: The 5% YoY top-line growth in Q3 (₹69 cr vs ₹65–66 cr) reflected a combination of pricing and volume; the 17%/2% split was a 9M figure, not a Q3 figure, which management acknowledged as a presentation oversight.
- Freight pass-through cut both ways: Ocean freight rates dropped over the last 3–4 months, and since ~65–70% of exports are on CIF terms, the freight component embedded in revenue fell, mechanically reducing the top line even before any volume change.
- O&M income is growing but margin-dilutive: O&M income rose to ~15% of revenue in Q3 (normally ~6%), and because O&M manpower cost runs at ~60–63% of that segment, it pushed employee costs higher QoQ. The new ONGC Dahej contract added ~120 team members, with revenues only just beginning.
- Other income boosted by forex: 9M other income rose to ₹5 cr (vs ₹2.63 cr full-year last year), primarily from a ~₹3 cr foreign exchange gain on dollar appreciation, plus interest on margin money and fixed deposits.
Capacity Expansion & Capex
- Dahej and Jhagadia expansion: Total capex of ₹58–60 cr is underway; capitalization is expected in Q2 FY24 when commercial production commences, with sales visible on the balance sheet by Q3 FY24. Dahej faces a 2–3 month delay from the original schedule due to civil works and equipment delivery sequencing.
- Peak sales potential: At 21,000 tonnes capacity and 90% utilization, with current average realization and an improving product mix, management expects the revenue run-rate to be at least at current levels if not higher.
- CCS plant: The environmental clearance application has been submitted, with approval expected within 6 months. Civil work will commence immediately upon approval, and commissioning is targeted at 15 months (optimistic) to 18 months (pessimistic) from that point.
- Utilization snapshot: 9M overall utilization was 91%; Dahej ran at 85%, Jhagadia at 97%, and Hyderabad at 94%. Q3 saw a slight volume drop, but management hopes to regain utilization in Q4.
Diversification: Premix, OTC, API & Acquisitions
- Premix and OTC are off to a slow start: Revenue in FY23 will be only a couple of crores each, well below the earlier estimate of ₹10–15 cr, due to dull international markets and slower customer sampling. Management acknowledged the earlier estimate was an overestimation. For FY24, each is expected to contribute at least ₹10–12 cr.
- API and intermediates strategy: The company is actively exploring options but nothing is firmed up. The stated approach is to target USFDA-approved facilities serving developed markets (US, EU) for better realization and margins, leveraging the same customer base of formulators it already serves in excipients. It plans to start with generics to cover costs, then gradually move toward regulated markets via DMF filings and ANDAs.
- Acquisition pipeline: The preferential allotment fund-raise (25% upfront, balance 75% over 18 months) is earmarked for possible acquisitions that synergize with the product portfolio and customer base. Discussions are active but nothing is finalized; management will seek regulatory approval when a target is firmed up.
- New divisions' margin profile: Individually, new divisions may operate around ±100 bps of the current 21–22% margin. Cumulatively, as a vertically integrated pharma player, management expects overall margin benefit and customer perception to improve, with far better margins as divisions gain ground.
Amit Raj Sinha: "I believe that when the company is small and flexible, there is a lot possible. When it becomes big and rigid, it gets difficult. The downside of getting into all of this is absolutely nil. There is no downside, there is no negative."
Costs, Margins & Employee Expense
- Employee cost jumped QoQ: The rise from ₹8.29 cr to ₹10 cr was driven by three factors: field staff deployed for OTC and generics where revenue is yet to generate; O&M income rising to ~15% of revenue (normally ~6%), carrying ~60–63% manpower cost; and the new ONGC Dahej O&M contract adding ~120 team members with revenues only just starting.
- Other expenses dipped on freight: The QoQ decline in other expenses was driven by lower freight costs, which are a pass-through element that also reduces revenue, creating a net-off effect.
- EBITDA and profitability improved on the back of a high-margin product mix, cost-effective manufacturing, and effective inventory management, with freight and raw material cost increases successfully passed on to customers.
Governance & Capital Allocation
- Trademark ownership question unresolved: An analyst challenged why trademarks and copyrights from R&D reside with a promoter Trust rather than the company, arguing it disadvantages minority shareholders. Management responded that Amit Raj Sinha developed the brands personally and granted free use until 2025, with royalty thereafter. The suggestion to shift royalty from a percentage of sales to a percentage of profits is under consideration, but the core question of why ownership sits with the promoter Trust was not directly answered.
- Promoter funding for preferential allotment: Promoters will raise personal debt to fund their ~₹150–160 cr commitment in the preferential issue. Management framed this as a signal of promoter confidence, arguing that if the promoter is confident enough to borrow and invest, other shareholders should view it positively.
- Non-promoter allottee selection: When asked about the process for selecting non-promoter allottees, management stated no specific structure was followed and that it was internal to the non-promoter group, without detailing criteria.
Amit Raj Sinha: "Saket sir, I would put it the other way. I would put it that if the promoter is so confident in borrowing money and growing the company, everybody else should be happy about it."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q4 revenue run-rate | ₹80 cr/quarter endorsed as a fair estimate | Q4 FY23 through Q2 FY24 |
| Dahej & Jhagadia capex commercialization | ₹58–60 cr capex turning into sales on balance sheet | Q3 FY24 (Q2 FY24 commissioning) |
| CCS plant environmental clearance | Approval expected; civil work commences immediately upon receipt | Within 6 months |
| CCS plant commissioning | 15 months (optimistic) to 18 months (pessimistic) from approval | 15–18 months post-EC approval |
| Premix & OTC revenue contribution | At least ₹10–12 cr each | FY24 |
| Overall revenue growth target | 20% driven by new capacities in core product | FY24 |
| Segmental reporting (MCC vs O&M) | To be provided if required | From next quarter onwards |
| Long-term growth aspiration | Minimum 25% YoY while defending EBITDA margins | 5-year horizon |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Operating income | ₹69 cr, up ~5% YoY |
| EBITDA | ₹14 cr, up ~10% YoY |
| EBITDA margin | 20.35% |
| Net profit | ~₹10 cr, up ~3% YoY |
| PAT margin | 14.24% |
| 9M FY23 operating income | ~₹230 cr, up 29% YoY |
| 9M FY23 EBITDA | ₹46.5 cr, up 21% YoY |
| 9M FY23 EBITDA margin | 20.25% |
| 9M FY23 net profit | ~₹36 cr, up 27.5% YoY |
| 9M FY23 PAT margin | 15.77% |
| 9M FY23 revenue growth split | 2% volume growth and 17% realization growth YoY |
| 9M FY23 capacity utilization | 91% overall; Dahej 85%, Jhagadia 97%, Hyderabad 94% |
| 9M FY23 volume sold | 9,859 metric tons, up 2% YoY from 9,567 metric tons |
| 9M FY23 average realization | ₹217.14 per unit |
| O&M income | ₹6.85 cr in Q3; ₹17.67 cr in 9M FY23 vs ~₹13.4 cr in prior full year |
| Employee cost | ₹10 cr, up from ₹8.29 cr QoQ, driven by field staff deployment for OTC/generics and ONGC O&M contract |
| Total capacity | >13,800 MTPA currently, expanding to 21,000 MTPA via ongoing CAPEX |
| CAPEX for Dahej and Jhagadia expansion | ~₹58–60 cr, to be capitalized upon commercial production expected by Q2 FY24 |
| Fund-raise planned | ~₹300 cr for expansion into intermediates and APIs |
| Preferential warrant issuance | 1.10 cr warrants; 50 lakh from promoter category, 25% upfront payment, balance 75% over 18 months |
| Premix and OTC expected revenue in FY23 | ~₹2 cr each from trial lots and dispatches |
| Premix and OTC expected revenue in FY24 | at least ₹10–12 cr each |
| Full-year FY23 volume guidance | ~13,000 to nearly 14,000 metric tons |
| Working capital cycle | ~90 days |
| 9M FY23 other income | ₹5 cr, including ~₹3 cr foreign exchange gain |